scholarly journals GLP‐1 receptor agonists and their cardiovascular benefits ‐ the role of the GLP‐1 receptor

2021 ◽  
Author(s):  
Johanna Helmstädter ◽  
Karin Keppeler ◽  
Leonie Küster ◽  
Thomas Münzel ◽  
Andreas Daiber ◽  
...  
Keyword(s):  
Receptor Agonists

Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era

2020 ◽  
Vol 20 ◽  
Author(s):  
Giuseppe Lassandro ◽  
Valentina Palladino ◽  
Giovanni Carlo Del Vecchioa ◽  
Viviana Valeria Palmieri ◽  
Paola Carmela Corallo ◽  
...  
Keyword(s):  
Immune Thrombocytopenia ◽  
Treatment Options ◽  
Thrombopoietin Receptor Agonists ◽  
Receptor Agonists ◽  
Thrombopoietin Receptor ◽  
Related Quality ◽  
Health Related

Background and Objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood. The management of ITP in children is controversial, requiring personalized assessment of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, have been shown to be safety and effective for the treatment of pediatric ITP. The aim of our research is defining the role of thrombopoietin receptor agonists in the management of pediatric ITP. Method: This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in clinical routine, highlighting their key role in management of the disease. Results: Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with minor side effects. Conclusion: Although TPO-RAs long term efficacy and safety still require further investigations, their use is gradually expanding in clinical practice of children with ITP.

scholarly journals The role of GLP-1/GIP receptor agonists in Alzheimer’s disease

2020 ◽  
Vol 29 (6) ◽  
pp. 661-668
Author(s):  
Chun jiang Yu ◽  
Ling ling Song ◽  
Zhen nan Zhai ◽  
Ye Tao ◽  
Ying Zhang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Receptor Agonists ◽  
Gip Receptor

Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists

2017 ◽  
Vol 31 (11) ◽  
pp. 1403-1418 ◽  
Author(s):  
Guy A Higgins ◽  
Fiona D Zeeb ◽  
Paul J Fletcher
Keyword(s):  
Lifestyle Modification ◽  
Conditioned Reward ◽  
Receptor Agonists ◽  
Subsequent Phase ◽  
Obese Subjects ◽  
Clinically Significant ◽  
Treatment Of Obesity ◽  
Phase Ii And Iii ◽  
Modest Effect

The selective 5-HT2C receptor agonist lorcaserin entered clinical obesity trials with the prevalent view that satiety was a primary mechanism of action. Subsequent Phase II and III trials demonstrated efficacy in terms of weight loss, although the overall effect size (~3% placebo-corrected change) is considered modest. Lorcaserin has been approved by the FDA for the treatment of obesity with lifestyle modification, but since its introduction in 2013 its sales are in decline, probably due to its overall modest effect. However, in some individuals, lorcaserin has a much more clinically significant effect (i.e. >10% placebo-corrected change), although what common features, if any, define these high responders is presently unknown. In the present article we highlight the evidence that alternative mechanisms to satiety may contribute to the anti-obesity effect of lorcaserin, namely effects on constructs of primary and conditioned reward and impulsivity. This may better inform the clinical evaluation of lorcaserin (and any future 5-HT2C receptor agonists) to subgroups of obese subjects characterized by overeating due to maladaptive impulsivity and reward mechanisms. One such population might be individuals diagnosed with binge eating disorder.

scholarly journals Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases

2019 ◽  
Vol 9 ◽  
Author(s):  
Carl Spana ◽  
Andrew W. Taylor ◽  
David G. Yee ◽  
Marie Makhlina ◽  
Wei Yang ◽  
...  
Keyword(s):  
Receptor Agonists ◽  
Immunological Diseases

Role of serotonergic neurons in the maintenance of the 10-Hz rhythm in sympathetic nerve discharge

1996 ◽  
Vol 270 (1) ◽  
pp. R174-R181 ◽  
Author(s):  
H. S. Orer ◽  
M. E. Clement ◽  
S. M. Barman ◽  
S. Zhong ◽  
G. L. Gebber ◽  
...  
Keyword(s):  
Sympathetic Nerve ◽  
Peak Frequency ◽  
Inhibitory Effects ◽  
Receptor Agonists ◽  
Naturally Occurring ◽  
Medullary Raphe ◽  
Receptor Agonists And Antagonists ◽  
Raphe Neurons ◽  
Nerve Discharge

We studied the effects of serotonin (5-HT)-receptor agonists and antagonists on the naturally occurring 10-Hz rhythm in sympathetic nerve discharge (SND) of urethan-anesthetized, baroreceptor-denervated cats. Intravenous doses of the 5-HT1A-receptor agonists 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT) and U-93385E, which inhibit the firing of serotonergic medullary raphe neurons, decreased the power in the 10-Hz band of SND without affecting the power at frequencies < or = 6 Hz. The inhibitory effects of 8-OH-DPAT and U-93385E were reversed by the 5-HT1A-receptor antagonists spiperone and WAY-100135. Microinjection of 8-OH-DPAT into medullary raphe nuclei also selectively eliminated the 10-Hz rhythm in SND. Intravenous administration of the 5-HT2-receptor antagonist methysergide blocked the 10-Hz rhythm in SND, whereas the 5-HT2-receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane increased peak frequency and power in the 10-Hz band of SND. Microinjection of N-methyl-D-aspartic acid into the medullary raphe also enhanced the 10-Hz rhythm in SND. These data support the view that the naturally occurring discharges of serotonergic medullary raphe neurons preferentially enhance the 10-Hz rhythm in SND.

Sign in / Sign up

Export Citation Format

Share Document